Loading…
Employees: 370
Size InBody (041830.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $378M, the 410th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩42,050 on 6 Nov 2026.
Performance Over six months the shares gained 42.5%, against -20.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 21.3% over the last twelve months (peer median +6.8%); the operating margin is 18.9% (peer median 8.1%).
Valuation It trades at 11.4× forward earnings against a peer median of 19.2× (4th cheapest of 11).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -25 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.1 points above its cost of capital (7.2% WACC).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩264B | ₩234B | ₩204B | ₩170B | ₩160B |
| Revenue growth | — | +14% | +20% | +6% | — |
| Gross profit | ₩197B | ₩174B | ₩153B | ₩128B | ₩117B |
| EBITDA | ₩59.1B | ₩44.7B | ₩42.7B | ₩44.3B | ₩46.1B |
| Net income | ₩46.5B | ₩30.6B | ₩33.1B | ₩36.7B | ₩33.8B |
| Free cash flow | ₩33.4B | ₩28.9B | ₩22.3B | ₩31.2B | ₩25.0B |
| Capital expenditure | ₩7.05B | ₩7.42B | ₩7.55B | ₩7.64B | ₩6.02B |
| Total debt | ₩8.01B | ₩10.3B | ₩8.42B | ₩6.08B | ₩6.40B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 041830.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.8% | -10.9% | 5th lowest of 21 |
| 6-month return | +42.5% | -20.2% | 3rd highest of 20 |
| Distance from 52-week high | -42.8% | -40.0% | 9th lowest of 21 |
| Revenue growth (TTM) | +21.3% | +6.8% | 6th highest of 20 |
| Operating margin | 18.9% | 8.1% | 6th highest of 20 |
| Forward P/E | 11.4× | 19.2× | 4th cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | -7.6% | -5.3% | 7th least demanding of 13 |
| Growth delivered (Del g) | +16.9% | +1.6% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -24.5 pp | -0.3 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +10.1 pp | +5.6 pp | 8th highest of 19 |
| EV / EBITDA | 6.4× | 9.1× | 3rd cheapest of 9 |
| Net debt / EBITDA | -2.3× | -3.7× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 11.4× | -7.6% | +16.9% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 994.0× | 22.4% | -5.1% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 38.5× | 20.0% | +4.4% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | n/a | n/a | n/a |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 20.0× | 39.0% | +5.2% |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 8.3× | -18.5% | +15.4% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | n/a | -8.0% | -6.6% |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 27.5× | -2.5% | -6.0% |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | n/a | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | n/a | n/a | n/a |
| Cerus CERS | United States | $408M | -23% | +14% | -12% | n/a | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 18.4× | 9.8% | +3.4% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 10.1× | -9.1% | +247.0% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |